Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 2 (CDK2)/cyclin E inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Researchers from Incyte Research Institute presented the discovery of a cyclin-dependent kinase 2 (CDK2) inhibitor, INCB-123667, being developed for the treatment of cyclin E dysregulated cancers.
